首页 > 最新文献

Colombia Medica最新文献

英文 中文
Artificial intelligence in scientific writing: What are the ethical boundaries? - A Reflection inspired by the myth of Prometheus. 科学写作中的人工智能:伦理界限是什么?- 受普罗米修斯神话启发的思考。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-12-30 eCollection Date: 2023-10-01 DOI: 10.25100/cm.v54i4.5954
Raúl Alberto Aguilera-Eguía, Ángel Roco Videla, Héctor Fuentes-Barria, Cristian Yáñez-Baeza
{"title":"Artificial intelligence in scientific writing: What are the ethical boundaries? - A Reflection inspired by the myth of Prometheus.","authors":"Raúl Alberto Aguilera-Eguía, Ángel Roco Videla, Héctor Fuentes-Barria, Cristian Yáñez-Baeza","doi":"10.25100/cm.v54i4.5954","DOIUrl":"10.25100/cm.v54i4.5954","url":null,"abstract":"","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":"54 4","pages":"e7005954"},"PeriodicalIF":0.7,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11360813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proprioceptive rehabilitation strategies in posttraumatic wrist injuries. Scoping review. 腕部创伤后的知觉康复策略。范围审查。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-12-30 eCollection Date: 2023-10-01 DOI: 10.25100/cm.v54i4.5709
Lida J Sánchez-Montoya, Diana P Sánchez, Leidy Tatiana Ordoñez-Mora

Background: The proprioceptive approach can effectively improve strength, mobility, edema reduction, and pain reduction, which in turn has a positive impact on functionality.

Objective: To identify proprioceptive rehabilitation strategies reported in the literature in adults with traumatic wrist injuries.

Methods: A scoping review was performed following the parameters of the Prisma ScR strategy. We included research with adult patients diagnosed with posttraumatic wrist injuries who used proprioceptive rehabilitation. Pain, functionality, strength, joint mobility ranges, and edema were evaluated.

Results: After removing duplicates and applying the exclusion criteria, a total of 123 articles were found, which left six articles, including 125 patients. Rehabilitation protocols based on proprioceptive neuromuscular facilitation and using sensorimotor tools that promote wrist recovery have been generated. In addition, other approaches have been established, such as motor imagery, which generates a work of identification and organization of movement, improving pain and manual function. However, longer follow-ups, standardization of the instruments used during proprioceptive intervention, and increasing the observed population are needed to generate a recommendation for early intervention and cost-benefit estimates.

Conclusion: Proprioceptive rehabilitation has demonstrated benefits in the recovery of the lower limb and hip or back. However, for the rehabilitation of traumatic wrist injuries, it is research pending. Well-described data and good quality designs are needed to routinely propose this strategy in the clinic.

背景:本体感觉疗法可有效改善患者的力量、活动能力、减轻水肿和疼痛,从而对患者的功能产生积极影响:本体感觉方法可以有效改善力量、活动能力、减轻水肿和疼痛,进而对功能产生积极影响:确定文献中报道的针对腕部外伤成人的本体感觉康复策略:方法:根据 Prisma ScR 策略的参数进行范围审查。我们纳入了对被诊断为腕部创伤后损伤的成年患者进行本体感觉康复的研究。对疼痛、功能、力量、关节活动范围和水肿进行了评估:结果:在去除重复文章并应用排除标准后,共找到 123 篇文章,其中有 6 篇文章涉及 125 名患者。基于本体感觉神经肌肉促进和使用感觉运动工具促进腕部恢复的康复方案已经产生。此外,还建立了其他方法,如运动想象,它能产生识别和组织运动的工作,改善疼痛和手动功能。然而,需要进行更长时间的随访,对本体感觉干预过程中使用的工具进行标准化,并增加观察人群,以便为早期干预和成本效益估算提出建议:结论:本体感觉康复对下肢、髋部或背部的恢复有明显的益处。然而,对于腕部外伤的康复,还有待于研究。要在临床上常规采用这一策略,需要有详尽的数据描述和高质量的设计。
{"title":"Proprioceptive rehabilitation strategies in posttraumatic wrist injuries. Scoping review.","authors":"Lida J Sánchez-Montoya, Diana P Sánchez, Leidy Tatiana Ordoñez-Mora","doi":"10.25100/cm.v54i4.5709","DOIUrl":"10.25100/cm.v54i4.5709","url":null,"abstract":"<p><strong>Background: </strong>The proprioceptive approach can effectively improve strength, mobility, edema reduction, and pain reduction, which in turn has a positive impact on functionality.</p><p><strong>Objective: </strong>To identify proprioceptive rehabilitation strategies reported in the literature in adults with traumatic wrist injuries.</p><p><strong>Methods: </strong>A scoping review was performed following the parameters of the Prisma ScR strategy. We included research with adult patients diagnosed with posttraumatic wrist injuries who used proprioceptive rehabilitation. Pain, functionality, strength, joint mobility ranges, and edema were evaluated.</p><p><strong>Results: </strong>After removing duplicates and applying the exclusion criteria, a total of 123 articles were found, which left six articles, including 125 patients. Rehabilitation protocols based on proprioceptive neuromuscular facilitation and using sensorimotor tools that promote wrist recovery have been generated. In addition, other approaches have been established, such as motor imagery, which generates a work of identification and organization of movement, improving pain and manual function. However, longer follow-ups, standardization of the instruments used during proprioceptive intervention, and increasing the observed population are needed to generate a recommendation for early intervention and cost-benefit estimates.</p><p><strong>Conclusion: </strong>Proprioceptive rehabilitation has demonstrated benefits in the recovery of the lower limb and hip or back. However, for the rehabilitation of traumatic wrist injuries, it is research pending. Well-described data and good quality designs are needed to routinely propose this strategy in the clinic.</p>","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":"54 4","pages":"e3005709"},"PeriodicalIF":0.7,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11360815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of central intermittent theta-burst stimulation combined with repetitive peripheral magnetic stimulation on upper limb function in stroke patients. 中枢间歇θ-脉冲刺激结合重复外周磁刺激对中风患者上肢功能的影响。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-12-30 eCollection Date: 2023-10-01 DOI: 10.25100/cm.v54i4.5766
Shangrong Jiang, Tingtin Han, Zhijie Zhang, Mingming Wen, Yongping Li

Background: Intermittent theta-burst stimulation and repetitive peripheral magnetic stimulation can improve motor function in poststroke patients, but the therapeutic effect of this combination remains unclear.

Objective: To determine the effects of central intermittent theta-burst stimulation and repetitive peripheral magnetic stimulation on upper limb function.

Methods: Fifty-six subacute stroke patients were randomly assigned to three groups: the CMS (n = 18), peripheral magnetic stimulation (PMS) (n = 19) and CPS (n = 19) groups. The CMS group received intermittent theta-burst stimulation and peripheral false stimulation, while the PMS group received repetitive peripheral magnetic stimulation and central false stimulation once a day for five days a week over four weeks. The CPS group received intermittent theta-burst stimulation and repetitive peripheral magnetic stimulation simultaneously once daily for four weeks. The Fugl-Meyer Assessment, Action Research Arm Test, Modified Barthel Index and Modified Ashworth Scale evaluated outcomes before and after four weeks of treatment.

Results: The motor function scores of all groups were significantly increased after treatment compared with before treatment, while the Modified Ashworth Scale score showed no significant change. There was a significant difference in the motor function score of the CPS group compared with that of the CMS and PMS groups, but there was no significant improvement in the Modified Ashworth Scale score.

Conclusion: Combining the two treatment methods can improve patients' motor function and daily living abilities but cannot improve muscle tone.

背景:间歇性θ-脉冲刺激和重复性外周磁刺激可以改善卒中后患者的运动功能,但这种组合的治疗效果仍不明确:目的:确定中枢间歇θ-脉冲刺激和重复外周磁刺激对上肢功能的影响:将 56 名亚急性中风患者随机分配到三组:CMS 组(18 人)、外周磁刺激组(19 人)和 CPS 组(19 人)。CMS组接受间歇性θ-脉冲刺激和外周假刺激,而PMS组接受重复性外周磁刺激和中枢假刺激,每天一次,每周五天,持续四周。CPS 组接受间歇性θ-脉冲刺激和重复性外周磁刺激,每天一次,持续四周。Fugl-Meyer 评估、行动研究手臂测试、改良 Barthel 指数和改良 Ashworth 量表对治疗四周前后的结果进行了评估:结果:与治疗前相比,治疗后各组的运动功能评分均有明显提高,而改良阿什沃斯量表评分则无明显变化。CPS组的运动功能评分与CMS组和PMS组相比有明显差异,但改良阿什沃斯量表评分没有明显改善:结论:两种治疗方法联合使用可改善患者的运动功能和日常生活能力,但不能改善肌张力。
{"title":"Effects of central intermittent theta-burst stimulation combined with repetitive peripheral magnetic stimulation on upper limb function in stroke patients.","authors":"Shangrong Jiang, Tingtin Han, Zhijie Zhang, Mingming Wen, Yongping Li","doi":"10.25100/cm.v54i4.5766","DOIUrl":"10.25100/cm.v54i4.5766","url":null,"abstract":"<p><strong>Background: </strong>Intermittent theta-burst stimulation and repetitive peripheral magnetic stimulation can improve motor function in poststroke patients, but the therapeutic effect of this combination remains unclear.</p><p><strong>Objective: </strong>To determine the effects of central intermittent theta-burst stimulation and repetitive peripheral magnetic stimulation on upper limb function.</p><p><strong>Methods: </strong>Fifty-six subacute stroke patients were randomly assigned to three groups: the CMS (n = 18), peripheral magnetic stimulation (PMS) (n = 19) and CPS (n = 19) groups. The CMS group received intermittent theta-burst stimulation and peripheral false stimulation, while the PMS group received repetitive peripheral magnetic stimulation and central false stimulation once a day for five days a week over four weeks. The CPS group received intermittent theta-burst stimulation and repetitive peripheral magnetic stimulation simultaneously once daily for four weeks. The Fugl-Meyer Assessment, Action Research Arm Test, Modified Barthel Index and Modified Ashworth Scale evaluated outcomes before and after four weeks of treatment.</p><p><strong>Results: </strong>The motor function scores of all groups were significantly increased after treatment compared with before treatment, while the Modified Ashworth Scale score showed no significant change. There was a significant difference in the motor function score of the CPS group compared with that of the CMS and PMS groups, but there was no significant improvement in the Modified Ashworth Scale score.</p><p><strong>Conclusion: </strong>Combining the two treatment methods can improve patients' motor function and daily living abilities but cannot improve muscle tone.</p>","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":"54 4","pages":"e2005766"},"PeriodicalIF":0.7,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11341120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac resynchronization therapy in acute heart failure and left bundle-branch block in a real-life registry. 心脏再同步化疗法在急性心力衰竭和左束支传导阻滞中的实际应用登记。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-12-29 eCollection Date: 2023-10-01 DOI: 10.25100/cm.v54i4.5850
Oriol Aguiló, Joan Carles Trullàs, Begoña Espinosa, Pedro López-Ayala, Víctor Gil, María Luisa López-Grima, Pablo Herrero-Puente, Javier Jacob, María Pilar López-Díez, José Manuel Garrido, Javier Millán, Alfons Aguirre, Pascual Piñera, Christian E Müller, Pere Llorens, Òscar Miro

Objectives: To determine the prevalence, characteristics, timing of implementation and prognosis of patients with left bundle branch block (LBBB) and acute heart failure (AHF) treated with cardiac resynchronization therapy (CRT) in a real-life registry.

Methods: We analysed the characteristics of patients with AHF and LBBB at the time of inclusion in the EAHFE (Epidemiology Acute Heart Failure Emergency) cohort to determine the indication for CRT, the timing of implementation and its impact on 10-year all-cause mortality.

Results: 729 patients with a median age of 82 years and there was a high burden of comorbidities and functional dependence. The median left-ventricle ejection fraction (LVEF) was 40%. Forty-six (6%) patients were treated with CRT at some point during follow-up, with a median time of delay for CRT implementation of 960 (IQR=1,147 days) and at least 108 more untreated patients fulfilled criteria for CRT. Patients receiving CRT were younger, had different comorbidities, less functional dependence (higher Barthel index) and lower LVEF values. The median follow-up was 5.7 years (95% CI: 5.6-5.8) and CRT was not associated with changes in 10-year mortality (adjusted HR 1.33, 95% CI: 0.72-2.48; p-value 0.4). When compared with untreated patients fulfilling criteria for CRT, very similar results were observed (adjusted HR 1.34, 95% CI: 0.67-2.68).

Conclusions: CRT implementation was delayed and underused in patients with AHF and LBBB. Under these circumstances, CRT is not associated with a reduction in all-cause mortality in the long term.

目的在一项真实的登记中确定接受心脏再同步化疗法(CRT)治疗的左束支传导阻滞(LBBB)和急性心力衰竭(AHF)患者的患病率、特征、实施时间和预后:我们分析了AHF和LBBB患者纳入EAHFE(流行病学急性心力衰竭急诊)队列时的特征,以确定CRT的适应症、实施时机及其对10年全因死亡率的影响:729名患者的中位年龄为82岁,合并症和功能依赖性较高。左心室射血分数(LVEF)中位数为 40%。46名(6%)患者在随访期间的某个阶段接受了CRT治疗,CRT实施的中位延迟时间为960天(IQR=1,147天),另有至少108名未经治疗的患者符合CRT标准。接受CRT治疗的患者更年轻,合并症不同,功能依赖性较低(巴特尔指数较高),LVEF值较低。中位随访时间为 5.7 年(95% CI:5.6-5.8 年),CRT 与 10 年死亡率的变化无关(调整后 HR 1.33,95% CI:0.72-2.48;P 值 0.4)。与符合CRT标准的未接受治疗的患者相比,结果非常相似(调整后HR为1.34,95% CI为0.67-2.68):结论:CRT在AHF和LBBB患者中延迟实施且使用不足。结论:AHF和LBBB患者延迟实施CRT且使用不足,在这种情况下,CRT与长期降低全因死亡率无关。
{"title":"Cardiac resynchronization therapy in acute heart failure and left bundle-branch block in a real-life registry.","authors":"Oriol Aguiló, Joan Carles Trullàs, Begoña Espinosa, Pedro López-Ayala, Víctor Gil, María Luisa López-Grima, Pablo Herrero-Puente, Javier Jacob, María Pilar López-Díez, José Manuel Garrido, Javier Millán, Alfons Aguirre, Pascual Piñera, Christian E Müller, Pere Llorens, Òscar Miro","doi":"10.25100/cm.v54i4.5850","DOIUrl":"10.25100/cm.v54i4.5850","url":null,"abstract":"<p><strong>Objectives: </strong>To determine the prevalence, characteristics, timing of implementation and prognosis of patients with left bundle branch block (LBBB) and acute heart failure (AHF) treated with cardiac resynchronization therapy (CRT) in a real-life registry.</p><p><strong>Methods: </strong>We analysed the characteristics of patients with AHF and LBBB at the time of inclusion in the EAHFE (Epidemiology Acute Heart Failure Emergency) cohort to determine the indication for CRT, the timing of implementation and its impact on 10-year all-cause mortality.</p><p><strong>Results: </strong>729 patients with a median age of 82 years and there was a high burden of comorbidities and functional dependence. The median left-ventricle ejection fraction (LVEF) was 40%. Forty-six (6%) patients were treated with CRT at some point during follow-up, with a median time of delay for CRT implementation of 960 (IQR=1,147 days) and at least 108 more untreated patients fulfilled criteria for CRT. Patients receiving CRT were younger, had different comorbidities, less functional dependence (higher Barthel index) and lower LVEF values. The median follow-up was 5.7 years (95% CI: 5.6-5.8) and CRT was not associated with changes in 10-year mortality (adjusted HR 1.33, 95% CI: 0.72-2.48; p-value 0.4). When compared with untreated patients fulfilling criteria for CRT, very similar results were observed (adjusted HR 1.34, 95% CI: 0.67-2.68).<b></b></p><p><strong>Conclusions: </strong>CRT implementation was delayed and underused in patients with AHF and LBBB. Under these circumstances, CRT is not associated with a reduction in all-cause mortality in the long term.</p>","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":"54 4","pages":"e2015850"},"PeriodicalIF":0.7,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis. 一组哥伦比亚 AL 淀粉样变性患者的临床特征和预后。
IF 1.1 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-30 eCollection Date: 2023-07-01 DOI: 10.25100/cm.v54i3.5667
Jorge Andrés Lacouture Fierro, Daniel Andrés Ribero Vargas, Juanita Sánchez Cano, Lina Maria Gaviria Jaramillo, Oliver Gerardo Perilla Suarez, Kenny Mauricio Galvez Cárdenas, Sigifredo Ospina Ospina

Background: Amyloid light chain (AL) amyloidosis is characterized by amyloid fibril deposition derived from monoclonal immunoglobulin light chains, resulting in multiorgan dysfunction. Limited data exist on the clinical features of AL amyloidosis.

Objective: This study aims to describe the clinical characteristics, treatments, and outcomes in Colombian patients with AL amyloidosis.

Methods: A retrospective descriptive study was conducted at three high-complexity centers in Medellín, Colombia. Adults with AL amyloidosis diagnosed between 2012 and 2022 were included. Clinical, laboratory, histological, treatment, and survival data were analyzed.

Results: The study included 63 patients. Renal involvement was most prevalent (66%), followed by cardiac involvement (61%). Multiorgan involvement occurred in 61% of patients. Amyloid deposition was most commonly detected in renal biopsy (40%). Bortezomib-based therapy was used in 68%, and 23.8% received high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HDCT-ASCT). Hematological response was observed in 95% of patients with available data. Cardiac and renal organ responses were 15% and 14%, respectively. Median overall survival was 45.1 months (95% CI: 22.2-63.8). In multivariate analysis, cardiac involvement was significantly associated with inferior overall survival (HR 3.27; 95% CI: 1.23-8.73; p=0.018), HDCT-ASCT had a non-significant trend towards improved overall survival (HR 0.25; 95% CI: 0.06-1.09; p=0.065).

Conclusions: In this study of Colombian patients with AL amyloidosis, renal involvement was more frequent than cardiac involvement. Overall survival and multiorgan involvement were consistent with data from other regions of the world. Multivariate analysis identified cardiac involvement and HDCT-AHCT as possible prognostic factors.

背景:淀粉样轻链(AL)淀粉样变性的特征是由单克隆免疫球蛋白轻链产生的淀粉样纤维沉积,导致多器官功能障碍。有关AL淀粉样变性临床特征的数据有限:本研究旨在描述哥伦比亚 AL 淀粉样变性患者的临床特征、治疗方法和结果:在哥伦比亚麦德林市的三家高复杂性中心开展了一项回顾性描述性研究。研究纳入了2012年至2022年期间确诊的AL淀粉样变性成人患者。研究分析了临床、实验室、组织学、治疗和生存数据:研究共纳入 63 名患者。肾脏受累的比例最高(66%),其次是心脏受累(61%)。61%的患者出现多器官受累。肾活检最常发现淀粉样沉积(40%)。68%的患者接受了以硼替佐米为基础的治疗,23.8%的患者接受了大剂量化疗和自体造血干细胞移植(HDCT-ASCT)。在有数据可查的患者中,95%的患者出现了血液学反应。心脏和肾脏器官反应分别为15%和14%。中位总生存期为45.1个月(95% CI:22.2-63.8个月)。在多变量分析中,心脏受累与较差的总生存期显著相关(HR 3.27;95% CI:1.23-8.73;P=0.018),HDCT-ASCT对总生存期的改善趋势不显著(HR 0.25;95% CI:0.06-1.09;P=0.065):在这项针对哥伦比亚AL淀粉样变性患者的研究中,肾脏受累比心脏受累更为常见。总生存率和多器官受累情况与世界其他地区的数据一致。多变量分析确定心脏受累和HDCT-AHCT是可能的预后因素。
{"title":"Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis.","authors":"Jorge Andrés Lacouture Fierro, Daniel Andrés Ribero Vargas, Juanita Sánchez Cano, Lina Maria Gaviria Jaramillo, Oliver Gerardo Perilla Suarez, Kenny Mauricio Galvez Cárdenas, Sigifredo Ospina Ospina","doi":"10.25100/cm.v54i3.5667","DOIUrl":"https://doi.org/10.25100/cm.v54i3.5667","url":null,"abstract":"<p><strong>Background: </strong>Amyloid light chain (AL) amyloidosis is characterized by amyloid fibril deposition derived from monoclonal immunoglobulin light chains, resulting in multiorgan dysfunction. Limited data exist on the clinical features of AL amyloidosis.</p><p><strong>Objective: </strong>This study aims to describe the clinical characteristics, treatments, and outcomes in Colombian patients with AL amyloidosis.</p><p><strong>Methods: </strong>A retrospective descriptive study was conducted at three high-complexity centers in Medellín, Colombia. Adults with AL amyloidosis diagnosed between 2012 and 2022 were included. Clinical, laboratory, histological, treatment, and survival data were analyzed.</p><p><strong>Results: </strong>The study included 63 patients. Renal involvement was most prevalent (66%), followed by cardiac involvement (61%). Multiorgan involvement occurred in 61% of patients. Amyloid deposition was most commonly detected in renal biopsy (40%). Bortezomib-based therapy was used in 68%, and 23.8% received high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HDCT-ASCT). Hematological response was observed in 95% of patients with available data. Cardiac and renal organ responses were 15% and 14%, respectively. Median overall survival was 45.1 months (95% CI: 22.2-63.8). In multivariate analysis, cardiac involvement was significantly associated with inferior overall survival (HR 3.27; 95% CI: 1.23-8.73; <i>p</i>=0.018), HDCT-ASCT had a non-significant trend towards improved overall survival (HR 0.25; 95% CI: 0.06-1.09; <i>p</i>=0.065).</p><p><strong>Conclusions: </strong>In this study of Colombian patients with AL amyloidosis, renal involvement was more frequent than cardiac involvement. Overall survival and multiorgan involvement were consistent with data from other regions of the world. Multivariate analysis identified cardiac involvement and HDCT-AHCT as possible prognostic factors.</p>","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":"54 3","pages":"e2025667"},"PeriodicalIF":1.1,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10723764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms. 哥伦比亚 BCR-ABL 阴性骨髓增殖性肿瘤患者的 JAK2、CALR 和 MPL 基因突变概况。
IF 1.1 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-30 eCollection Date: 2023-07-01 DOI: 10.25100/cm.v54i3.5353
Ana Isabel Giraldo-Rincón, Sara Naranjo Molina, Natalia Gomez-Lopera, Daniel Aguirre Acevedo, Andrea Ucroz Benavidez, Kenny Gálvez Cárdenas, Francisco Cuellar Ambrosí, Jose Domingo Torres, Sigifredo Ospina, Katherine Palacio, Lina Gaviria Jaramillo, Carlos Mario Muñeton, Gonzalo Vasquez Palacio

Background: Among the chronic myeloproliferative neoplasms (MPNs) not associated with BCR-ABL mutations are polycythemia vera, primary myelofibrosis, and essential thrombocythemia. These diseases are caused by mutations in genes, such as the JAK2, MPL, and CALR genes, which participate in regulating the JAK-STAT signaling pathway.

Objective: This study aimed to establish the frequencies of mutations in the JAK2, MPL, and CALR genes in a group of Colombian patients with a negative clinical diagnosis of BCR-ABL chronic myeloproliferative neoplasms.

Methods: The JAK2 V617F and MPL W515K mutations and deletions or insertions in exon 9 of the CALR gene were analyzed in 52 Colombian patients with polycythemia vera, primary myelofibrosis, and essential thrombocythemia.

Results: The JAK2V617F mutation was carried by 51.9% of the patients, the CALR mutation by 23%, and the MPL mutation by 3.8%; 23% were triple-negative for the mutations analyzed. In these neoplasms, 6 mutation types in CALR were identified, one of which has not been previously reported. Additionally, one patient presented a double mutation in both the CALR and JAK2 genes. Regarding the hematological results for the mutations, significant differences were found in the hemoglobin level, hematocrit level, and platelet count among the three neoplasms.

Conclusion: Thus, this study demonstrates the importance of the molecular characterization of the JAK2, CALR and MPL mutations in Colombian patients (the genetic context of which remains unclear in the abovementioned neoplasms) to achieve an accurate diagnosis, a good prognosis, adequate management, and patient survival.

背景:与 BCR-ABL 基因突变无关的慢性骨髓增殖性肿瘤(MPNs)包括真性红细胞增多症、原发性骨髓纤维化和原发性血小板增多症。这些疾病是由参与调节 JAK-STAT 信号通路的 JAK2、MPL 和 CALR 等基因突变引起的:本研究旨在确定一组临床诊断为阴性 BCR-ABL 慢性骨髓增生性肿瘤的哥伦比亚患者的 JAK2、MPL 和 CALR 基因突变频率:方法:对52名患有真性红细胞增多症、原发性骨髓纤维化和原发性血小板增多症的哥伦比亚患者的JAK2 V617F和MPL W515K突变以及CALR基因第9外显子的缺失或插入进行了分析:结果:51.9%的患者携带JAK2V617F基因突变,23%的患者携带CALR基因突变,3.8%的患者携带MPL基因突变;23%的患者在所分析的基因突变中呈三阴性。在这些肿瘤中,发现了 6 种 CALR 突变类型,其中一种以前从未报道过。此外,一名患者的 CALR 和 JAK2 基因出现了双重突变。关于突变的血液学结果,三种肿瘤的血红蛋白水平、血细胞比容水平和血小板计数均存在显著差异:因此,本研究表明,对哥伦比亚患者的 JAK2、CALR 和 MPL 基因突变(上述肿瘤的遗传背景仍不清楚)进行分子鉴定对于准确诊断、良好预后、适当治疗和患者生存具有重要意义。
{"title":"JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.","authors":"Ana Isabel Giraldo-Rincón, Sara Naranjo Molina, Natalia Gomez-Lopera, Daniel Aguirre Acevedo, Andrea Ucroz Benavidez, Kenny Gálvez Cárdenas, Francisco Cuellar Ambrosí, Jose Domingo Torres, Sigifredo Ospina, Katherine Palacio, Lina Gaviria Jaramillo, Carlos Mario Muñeton, Gonzalo Vasquez Palacio","doi":"10.25100/cm.v54i3.5353","DOIUrl":"10.25100/cm.v54i3.5353","url":null,"abstract":"<p><strong>Background: </strong>Among the chronic myeloproliferative neoplasms (MPNs) not associated with BCR-ABL mutations are polycythemia vera, primary myelofibrosis, and essential thrombocythemia. These diseases are caused by mutations in genes, such as the JAK2, MPL, and CALR genes, which participate in regulating the JAK-STAT signaling pathway.</p><p><strong>Objective: </strong>This study aimed to establish the frequencies of mutations in the JAK2, MPL, and CALR genes in a group of Colombian patients with a negative clinical diagnosis of BCR-ABL chronic myeloproliferative neoplasms.</p><p><strong>Methods: </strong>The JAK2 V617F and MPL W515K mutations and deletions or insertions in exon 9 of the CALR gene were analyzed in 52 Colombian patients with polycythemia vera, primary myelofibrosis, and essential thrombocythemia.</p><p><strong>Results: </strong>The JAK2V617F mutation was carried by 51.9% of the patients, the CALR mutation by 23%, and the MPL mutation by 3.8%; 23% were triple-negative for the mutations analyzed. In these neoplasms, 6 mutation types in CALR were identified, one of which has not been previously reported. Additionally, one patient presented a double mutation in both the CALR and JAK2 genes. Regarding the hematological results for the mutations, significant differences were found in the hemoglobin level, hematocrit level, and platelet count among the three neoplasms.</p><p><strong>Conclusion: </strong>Thus, this study demonstrates the importance of the molecular characterization of the JAK2, CALR and MPL mutations in Colombian patients (the genetic context of which remains unclear in the abovementioned neoplasms) to achieve an accurate diagnosis, a good prognosis, adequate management, and patient survival.</p>","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":"54 3","pages":"e2035353"},"PeriodicalIF":1.1,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10726695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human intelligence for authors, reviewers and editors using artificial intelligence. 利用人工智能为作者、审稿人和编辑提供人类智能。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-30 eCollection Date: 2023-07-01 DOI: 10.25100/cm.v54i3.5867
Mauricio Palacios Gomez
{"title":"Human intelligence for authors, reviewers and editors using artificial intelligence.","authors":"Mauricio Palacios Gomez","doi":"10.25100/cm.v54i3.5867","DOIUrl":"10.25100/cm.v54i3.5867","url":null,"abstract":"","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":"54 3","pages":"e1005867"},"PeriodicalIF":0.7,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chatbots, generative AI, and scholarly manuscripts: WAME recommendations on chatbots and generative artificial intelligence in relation to scholarly publications. 聊天机器人、生成式人工智能和学术手稿:WAME关于与学术出版物有关的聊天机器人和生成式人工智能的建议。
IF 1.1 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-30 eCollection Date: 2023-07-01 DOI: 10.25100/cm.v54i3.5868
Chris Zielinski, Margaret A Winker, Rakesh Aggarwal, Lorraine E Ferris, Markus Heinemann, Jose Florencio Lapeña, Sanjay A Pai, Edsel Ing, Leslie Citrome, Murad Alam, Michael Voight, Farrokh Habibzadeh

This statement revises our earlier "WAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications" (January 20, 2023). The revision reflects the proliferation of chatbots and their expanding use in scholarly publishing over the last few months, as well as emerging concerns regarding lack of authenticity of content when using chatbots. These recommendations are intended to inform editors and help them develop policies for the use of chatbots in papers published in their journals. They aim to help authors and reviewers understand how best to attribute the use of chatbots in their work and to address the need for all journal editors to have access to manuscript screening tools. In this rapidly evolving field, we will continue to modify these recommendations as the software and its applications develop.

本声明修订了我们早前发布的《WAME 关于学术出版物中的 ChatGPT 和聊天机器人的建议》(2023 年 1 月 20 日)。此次修订反映了过去几个月聊天机器人的激增及其在学术出版中的广泛应用,以及新出现的对使用聊天机器人时内容缺乏真实性的担忧。这些建议旨在为编辑提供信息,帮助他们制定在期刊发表的论文中使用聊天机器人的政策。这些建议旨在帮助作者和审稿人了解如何在工作中最好地使用聊天机器人,并满足所有期刊编辑对稿件筛选工具的需求。在这个快速发展的领域,我们将随着软件及其应用的发展不断修改这些建议。
{"title":"Chatbots, generative AI, and scholarly manuscripts: WAME recommendations on chatbots and generative artificial intelligence in relation to scholarly publications.","authors":"Chris Zielinski, Margaret A Winker, Rakesh Aggarwal, Lorraine E Ferris, Markus Heinemann, Jose Florencio Lapeña, Sanjay A Pai, Edsel Ing, Leslie Citrome, Murad Alam, Michael Voight, Farrokh Habibzadeh","doi":"10.25100/cm.v54i3.5868","DOIUrl":"https://doi.org/10.25100/cm.v54i3.5868","url":null,"abstract":"<p><p>This statement revises our earlier \"WAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications\" (January 20, 2023). The revision reflects the proliferation of chatbots and their expanding use in scholarly publishing over the last few months, as well as emerging concerns regarding lack of authenticity of content when using chatbots. These recommendations are intended to inform editors and help them develop policies for the use of chatbots in papers published in their journals. They aim to help authors and reviewers understand how best to attribute the use of chatbots in their work and to address the need for all journal editors to have access to manuscript screening tools. In this rapidly evolving field, we will continue to modify these recommendations as the software and its applications develop.</p>","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":"54 3","pages":"e1015868"},"PeriodicalIF":1.1,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival of patients living with HIV and cancer in Cali, Colombia. 哥伦比亚卡利市艾滋病毒携带者和癌症患者的生存情况。
IF 1.1 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-30 eCollection Date: 2023-07-01 DOI: 10.25100/cm.v54i3.5588
Luis Gabriel Parra-Lara, Juan Pablo Arango-Ibañez, Juan J Martínez-Arboleda, Juan C Bravo, Ángela R Zambrano, Paola Collazos, Francisco Andino, Angélica Badillo, Sebastián Estrada, Fernando Rosso

Background: People living with HIV have an increased risk of cancer compared to the general population. However, with the increase in life expectancy and advances in antiretroviral therapy, the survival of patients with cancer and HIV has changed.

Objective: To determine the survival of patients living with HIV and cancer in Cali, Colombia.

Methods: A retrospective cohort study was conducted at the Fundación Valle del Lili, Cali, Colombia. Data from the HIV database was crossed with data from the hospital and population-based cancer registries between 2011-2019. Patients <18 years, limited available clinical information on the diagnosis and treatment of HIV and cancer, and non-oncological tumor diagnosis were excluded.

Results: A total of 173 patients were included. The frequencies of AIDS-defining neoplasms were: Non-Hodgkin lymphoma (42.8%), Kaposi sarcoma (27.8%), and cervical cancer (4.6%). Overall survival was 76.4% (95% CI 68.9-82.3) at five years. Poorer survival was found in patients with AIDS-defining infections (56.9% vs. 77.8%, p=0.027) and non-AIDS-defining infections (57.8% vs. 84.2%, p=0.013), while there was better survival in patients who received antiretroviral therapy (65.9% vs. 17.9%, p=0.021) and oncological treatment (66.7% vs. 35.4%, p<0.001). The presence of non-AIDS-defining infections increases the risk of dying (HR = 2.39, 95% CI 1.05-5.46, p=0.038), while oncological treatment decreases it (HR = 0.33, 95% CI 0.14-0.80, p=0.014).

Conclusions: In people living with HIV, Non-Hodgkin lymphoma and Kaposi sarcoma are the most common neoplasms. Factors such as AIDS-associated and non-AIDS-associated infections have been identified as determinants of survival. Cancer treatment seems to improve survival.

背景:与普通人群相比,艾滋病病毒感染者罹患癌症的风险更高。然而,随着预期寿命的延长和抗逆转录病毒疗法的进步,癌症和艾滋病病毒感染者的存活率也发生了变化:确定哥伦比亚卡利市艾滋病病毒感染者和癌症患者的存活率:哥伦比亚卡利 Valle del Lili 基金会开展了一项回顾性队列研究。2011-2019年间,HIV数据库中的数据与医院和人口癌症登记处的数据进行了交叉分析。患者结果:共纳入 173 名患者。艾滋病定义肿瘤的发病率为非霍奇金淋巴瘤(42.8%)、卡波西肉瘤(27.8%)和宫颈癌(4.6%)。五年总生存率为 76.4%(95% CI 68.9-82.3)。艾滋病定义感染(56.9% 对 77.8%,P=0.027)和非艾滋病定义感染(57.8% 对 84.2%,P=0.013)患者的生存率较低,而接受抗逆转录病毒治疗(65.9% 对 17.9%,P=0.021)和肿瘤治疗(66.7% 对 35.4%,P=0.021)的患者生存率较高:在艾滋病毒感染者中,非霍奇金淋巴瘤和卡波西肉瘤是最常见的肿瘤。艾滋病相关感染和非艾滋病相关感染等因素已被确定为影响存活率的决定性因素。癌症治疗似乎可以提高存活率。
{"title":"Survival of patients living with HIV and cancer in Cali, Colombia.","authors":"Luis Gabriel Parra-Lara, Juan Pablo Arango-Ibañez, Juan J Martínez-Arboleda, Juan C Bravo, Ángela R Zambrano, Paola Collazos, Francisco Andino, Angélica Badillo, Sebastián Estrada, Fernando Rosso","doi":"10.25100/cm.v54i3.5588","DOIUrl":"https://doi.org/10.25100/cm.v54i3.5588","url":null,"abstract":"<p><strong>Background: </strong>People living with HIV have an increased risk of cancer compared to the general population. However, with the increase in life expectancy and advances in antiretroviral therapy, the survival of patients with cancer and HIV has changed.</p><p><strong>Objective: </strong>To determine the survival of patients living with HIV and cancer in Cali, Colombia.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at the Fundación Valle del Lili, Cali, Colombia. Data from the HIV database was crossed with data from the hospital and population-based cancer registries between 2011-2019. Patients <18 years, limited available clinical information on the diagnosis and treatment of HIV and cancer, and non-oncological tumor diagnosis were excluded.</p><p><strong>Results: </strong>A total of 173 patients were included. The frequencies of AIDS-defining neoplasms were: Non-Hodgkin lymphoma (42.8%), Kaposi sarcoma (27.8%), and cervical cancer (4.6%). Overall survival was 76.4% (95% CI 68.9-82.3) at five years. Poorer survival was found in patients with AIDS-defining infections (56.9% vs. 77.8%, p=0.027) and non-AIDS-defining infections (57.8% vs. 84.2%, p=0.013), while there was better survival in patients who received antiretroviral therapy (65.9% vs. 17.9%, p=0.021) and oncological treatment (66.7% vs. 35.4%, p<0.001). The presence of non-AIDS-defining infections increases the risk of dying (HR = 2.39, 95% CI 1.05-5.46, p=0.038), while oncological treatment decreases it (HR = 0.33, 95% CI 0.14-0.80, p=0.014).</p><p><strong>Conclusions: </strong>In people living with HIV, Non-Hodgkin lymphoma and Kaposi sarcoma are the most common neoplasms. Factors such as AIDS-associated and non-AIDS-associated infections have been identified as determinants of survival. Cancer treatment seems to improve survival.</p>","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":"54 3","pages":"e2015558"},"PeriodicalIF":1.1,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10719985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinimetric properties of the Perme Intensive Care Unit Mobility Score -a multicenter study for minimum important difference and responsiveness analysis. Perme 重症监护室移动能力评分的临床测量特性--一项关于最小重要差异和响应性分析的多中心研究。
IF 1.1 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-25 eCollection Date: 2023-07-01 DOI: 10.25100/cm.v54i3.5580
Ricardo Kenji Nawa, Marcio Luiz Ferreira De Camillis, Monique Buttignol, Fernanda Machado Kutchak, Eder Chaves Pacheco, Louise Helena Rodrigues Gonçalves, Leonardo Miguel Correa Garcia, Karina Tavares Timenetsky, Luiz Alberto Forgiarini

Background: The use of instruments in clinical practice with measurement properties tested is highly recommended, in order to provide adequate assessment and measurement of outcomes.

Objective: To calculate the minimum clinically important difference (MCID) and responsiveness of the Perme Intensive Care Unit Mobility Score (Perme Score).

Methods: This retrospective, multicentric study investigated the clinimetric properties of MCID, estimated by constructing the Receiver Operating Characteristic (ROC). Maximizing sensitivity and specificity by Youden's, the ROC curve calibration was performed by the Hosmer and Lemeshow goodness-of-fit test. Additionally, we established the responsiveness, floor and ceiling effects, internal consistency, and predictive validity of the Perme Score.

Results: A total of 1.200 adult patients records from four mixed general intensive care units (ICUs) were included. To analyze which difference clinically reflects a relevant evolution we calculated the area under the curve (AUC) of 0.96 (95% CI: 0.95-0.98), and the optimal cut-off value of 7.0 points was established. No substantial floor (8.8%) or ceiling effects (4.9%) were observed at ICU discharge. However, a moderate floor effect was observed at ICU admission (19.3%), in contrast to a very low incidence of ceiling effect (0.6%). The Perme Score at ICU admission was associated with hospital mortality, OR 0.86 (95% CI: 0.82-0.91), and the predictive validity for ICU stay presented a mean ratio of 0.97 (95% CI: 0.96-0.98).

Conclusion: Our findings support the establishment of the minimum clinically important difference and responsiveness of the Perme Score as a measure of mobility status in the ICU.

背景:强烈建议在临床实践中使用经过测量特性测试的工具,以便对结果进行充分评估和测量:计算 Perme 重症监护室移动能力评分(Perme Score)的最小临床重要性差异(MCID)和响应性:这项多中心回顾性研究通过构建接收者操作特征曲线(ROC)来估算MCID的临床测量特性。通过Youden's最大化灵敏度和特异性,并通过Hosmer和Lemeshow拟合度检验进行ROC曲线校准。此外,我们还确定了渗透评分的反应性、最低和最高效应、内部一致性和预测有效性:结果:我们共纳入了来自四个混合型普通重症监护病房(ICU)的 1200 份成人患者病历。为了分析哪种差异在临床上反映了相关的演变,我们计算出曲线下面积(AUC)为 0.96(95% CI:0.95-0.98),并确定了最佳临界值为 7.0 分。在重症监护室出院时,没有观察到明显的下限效应(8.8%)或上限效应(4.9%)。不过,在重症监护室入院时观察到了中度的底限效应(19.3%),而上限效应的发生率非常低(0.6%)。ICU入院时的Perme评分与住院死亡率相关,OR值为0.86(95% CI:0.82-0.91),对ICU住院时间的预测有效性的平均比率为0.97(95% CI:0.96-0.98):我们的研究结果支持将最小临床重要差异和Perme评分的响应性作为衡量重症监护室移动能力状况的标准。
{"title":"Clinimetric properties of the Perme Intensive Care Unit Mobility Score -a multicenter study for minimum important difference and responsiveness analysis.","authors":"Ricardo Kenji Nawa, Marcio Luiz Ferreira De Camillis, Monique Buttignol, Fernanda Machado Kutchak, Eder Chaves Pacheco, Louise Helena Rodrigues Gonçalves, Leonardo Miguel Correa Garcia, Karina Tavares Timenetsky, Luiz Alberto Forgiarini","doi":"10.25100/cm.v54i3.5580","DOIUrl":"https://doi.org/10.25100/cm.v54i3.5580","url":null,"abstract":"<p><strong>Background: </strong>The use of instruments in clinical practice with measurement properties tested is highly recommended, in order to provide adequate assessment and measurement of outcomes.</p><p><strong>Objective: </strong>To calculate the minimum clinically important difference (MCID) and responsiveness of the Perme Intensive Care Unit Mobility Score (Perme Score).</p><p><strong>Methods: </strong>This retrospective, multicentric study investigated the clinimetric properties of MCID, estimated by constructing the Receiver Operating Characteristic (ROC). Maximizing sensitivity and specificity by Youden's, the ROC curve calibration was performed by the Hosmer and Lemeshow goodness-of-fit test. Additionally, we established the responsiveness, floor and ceiling effects, internal consistency, and predictive validity of the Perme Score.</p><p><strong>Results: </strong>A total of 1.200 adult patients records from four mixed general intensive care units (ICUs) were included. To analyze which difference clinically reflects a relevant evolution we calculated the area under the curve (AUC) of 0.96 (95% CI: 0.95-0.98), and the optimal cut-off value of 7.0 points was established. No substantial floor (8.8%) or ceiling effects (4.9%) were observed at ICU discharge. However, a moderate floor effect was observed at ICU admission (19.3%), in contrast to a very low incidence of ceiling effect (0.6%). The Perme Score at ICU admission was associated with hospital mortality, OR 0.86 (95% CI: 0.82-0.91), and the predictive validity for ICU stay presented a mean ratio of 0.97 (95% CI: 0.96-0.98).</p><p><strong>Conclusion: </strong>Our findings support the establishment of the minimum clinically important difference and responsiveness of the Perme Score as a measure of mobility status in the ICU.</p>","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":"54 3","pages":"e2005580"},"PeriodicalIF":1.1,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10714681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Colombia Medica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1